Wednesday, August 08, 2018 4:20:12 PM
Net loss for the three months ended June 30, 2018 (2018 Quarter) was $18.4 million, or $0.30 per share, as compared to a net loss of $13.4 million, or $0.36 per share, for the three months ended June 30, 2017 (2017 Quarter). Net loss for the 2018 Quarter includes license revenue of $10.0 million, related to the upfront payment received in connection with the license and collaboration agreement with Yakult in June 2018. Cash used in operating activities, excluding the upfront payment from Yakult, was $20.3 million for the 2018 Quarter.
Research and development expense for the 2018 Quarter was $12.4 million compared to $9.0 million for the 2017 Quarter. The $3.4 million increase from the 2017 Quarter to the 2018 Quarter was primarily related to an increase of $1.6 million in contract research organization expense for outsourced biology, development and clinical services, which includes the Company’s clinical trial costs, an increase of $1.0 million in personnel related costs, and an increase of $0.4 million in stock-based compensation expense.
General and administrative expense for the 2018 Quarter was $15.8 million compared to $4.4 million for the 2017 Quarter. The increase of $11.4 million from the 2017 Quarter to the 2018 Quarter primarily resulted from increases in consulting and professional fees of $5.2 million, including $3.6 million related to commercial launch preparation activities, and an increase in personnel related costs of $4.4 million.
As of June 30, 2018, Verastem Oncology had cash and cash equivalents of $168.7 million compared to $86.7 million of cash, cash equivalents and investments as of December 31, 2017.
The number of outstanding common shares as of June 30, 2018 was 73,579,699.
Financial Guidance
Based on the Company’s current operating plans, assuming a favorable regulatory decision and estimated revenue, it expects to have sufficient cash and cash equivalents to fund operations into 2020.
Recent VSTM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 08:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 10:01:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 10:00:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:30:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:30:17 PM
- Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference • Business Wire • 09/10/2024 08:05:00 PM
- Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting • Business Wire • 09/10/2024 11:30:00 AM
- Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 • Business Wire • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:10:42 PM
- Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates • Business Wire • 08/08/2024 08:05:00 PM
- Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer • Business Wire • 07/29/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 12:45:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/24/2024 09:06:01 PM
- Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants • Business Wire • 07/24/2024 03:20:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/23/2024 08:33:23 PM
- Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants • Business Wire • 07/23/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:01:17 PM
- Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics • Business Wire • 07/12/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 11:00:18 AM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 07/08/2024 11:30:00 AM
- Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes • Business Wire • 07/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 11:01:58 AM
- Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer • Business Wire • 05/24/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:24:02 PM
- Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer • Business Wire • 05/23/2024 09:01:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM